International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV

on behalf of the EORTC Quality of Life and the EORTC Head and Neck Cancer Groups

Research output: Contribution to journalArticle

Abstract

Background: We validated the new European Organisation for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN43). Methods: We enrolled 812 patients with head and neck cancer from 18 countries. Group 1 completed the questionnaire before therapy, and 3 and 6 months later. In group 2 (survivors), we determined test–retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed using Cronbach's Alpha, the scale structure with confirmatory factor analysis, and discriminant validity with known-group comparisons. Results: Cronbach's alpha was >0.70 in 10 of the 12 multi-item scales. All standardized factor loadings exceeded 0.40. The ICC was >0.70 in all but two scales. Differences in scale scores between known-groups were >10 points in 17 of the 19 scales. Sensitivity to change was found to be sufficient in 18 scales. Conclusions: Evidence supports the reliability and validity of the EORTC QLQ-HN43 as a measure of quality of life.

Original languageEnglish
JournalHead and Neck
DOIs
Publication statusAccepted/In press - Jan 1 2019

    Fingerprint

Keywords

  • chemoradiation
  • head and neck cancer
  • multimodal therapies
  • quality of life
  • validation

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this